| Affiliation: | 1. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;2. Laboratory Medicine Program, University Health Network, Toronto, ON, Canada;3. Department of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada;4. Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada;5. Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada |
| Abstract: | ![]()
Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation. |
